'Murky' path forward for Walgreens, Leerink Partners says
Updates
** Brokerage Leerink Partners cuts PT on drugstore chain Walgreens Boots Alliance WBA.O to $9 from $11
** Shares of Walgreens down 1.4% in early trading
** Company faces significantly higher interest expense in FY26 and FY27 and years of sales-leasebacks may complicate WBA's store closure plan, weighing on its cost-reduction efforts - brokerage
** WBA in June cut its FY24 profit forecast and said it would close underperforming U.S. stores as weak consumer spending hurt retail operations
** Company had then said it expects these challenges to persist into FY25 and was open to reviewing more store closures
** "Looking ahead to FY25 and beyond, we believe WBA's path forward remains murky at best" - Leerink
** Stock down ~65% YTD
Reporting by Mariam Sunny and Christy Santhosh
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
